Clinical trials: Lung Transplant Infection
Kidney Transplant Infection
Study of Pulmonary Infections (Pneumonia) in Kidney Transplant Recipients Admitted to Hospital
The investigators aimed to identify prognosis factors associated with in-hospital complications and assess the epidemiology, management, and outcomes of community-acquired pneumonia in a kidney transplant recipients' cohort.
- Trial name
- NCT05142748
- Where
- France
- Volunteers
- 132 people
- Sponsor
- CHU de Reims
Immune and Microbial Reconstitution, Systemic Viral Infection
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
This protocol serves as a mechanism to collect, store, and distribute bodily fluid and tissue samples obtained from Hematopoietic Cell Transplant (HCT) or novel immunotherapy patients and their donors at the Masonic Cancer Center…
- Conditions
- Immune and Microbial Reconstitution, Systemic Viral Infection, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
- Trial name
- NCT03557749
- Testing
- Blood Sample, Stool Sample, Urine Sample
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hepatitis C
DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)
The purpose of the study is to examine whether patients who have acute or early chronic hepatitis C virus (HCV) infection can be treated effectively and safely with an interferon-sparing regimen that combines a new direct acting…
- Trial name
- DARE-C II (NCT02156570)
- Testing
- Sofosbuvir and ribavirin
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Kirby Institute
Cystic Fibrosis
Tissue Collection From People With Cystic Fibrosis
This study will examine the relationship between bacterial products in lung infections in cystic fibrosis and disease severity. It will examine plasma and lung tissue from cystic fibrosis patients.
- Trial name
- NCT00015756
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hepatitis C Virus Infection
Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
The primary objectives of the study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (Vosevi®; SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks and of…
- Trial name
- POLARIS-4 (NCT02639247)
- Testing
- SOF/VEL/VOX, SOF/VEL
- Where
- 78 sites in United States, Australia and 6 more
- Volunteers
- 333 people
- Sponsor
- Gilead Sciences
Bronchoalveolar Lavage Fluid, Lung Infection
Diagnosis of Lung Complication After Allo-HSCT by Multiple Parameter System Through BAL
The aim of this study was to evaluate the diagnostic yield for lung complication after allo-HSCT by multiple parameter system through BAL.
- Trial name
- SHSYXY-BAL (NCT04051372)
- Testing
- Bronchoscopic Alveolar Lavage
- Volunteers
- 250 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Vaccine Response Impaired, Respiratory Syncytial Virus Infections
RSV Vaccine in Transplant Recipients
Adjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied.
- Conditions
- Vaccine Response Impaired, Respiratory Syncytial Virus Infections, Immune Suppression
- Trial name
- RSVax (NCT06593210)
- Testing
- Adjuvant, non-live RSV vaccine
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
COVID-19 Acute Respiratory Distress Syndrome, Immunosuppression
Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response
Introduction: Inadequate antibody response to mRNA SARS-CoV-2 vaccination has been described among kidney transplant recipients.
- Trial name
- WHO (NCT04961229)
- Testing
- The Pfizer mRNA-based BNT162b2 vaccine
- Volunteers
- 504 people
- Sponsor
- dafna yahav
Infections, Cytomegalovirus
Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.
The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+/R-) compared to a historical cohort of…
- Trial name
- LETERCOR (NCT06057194)
- Testing
- Letermovir 240 mg Oral Tablet
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Immunosuppression, Cancer
Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
Phase I/II Randomized Clinical Trial to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 hyperimmune serum. The study will include patients at early stage of COVID-19 with increased risk for severe disease due…
- Conditions
- Immunosuppression, Cancer, COVID-19, Other Complication of Kidney Transplant
- Trial name
- SOROCOV (NCT04834089)
- Testing
- AntiSARS-CoV-2 Serum
- Where
- 2 sites in Brazil
- Volunteers
- 618 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Immunization; Infection|Transplantation Infection|Influenza, Influenza
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center.
- Trial name
- NCT07192458
- Testing
- Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University Medical Center
Covid19, Myeloma Multiple
Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden
This retrospective observational cohort study aims to describe the impact of COVID-19 in patients treated with autologous stem cell transplantation (ASCT) for malignant disease in terms of risk factors, morbidity, need for…
- Conditions
- Covid19, Myeloma Multiple, Malignant Lymphoma, Hematologic Neoplasms
- Trial name
- AutoCOVID-19 (NCT04760184)
- Testing
- Autologous stem cell transplantation
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Uppsala University
Covid19
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
COVID-19 (SARS-CoV2 virus) was declared a global pandemic by the WHO on 11th March 2020. Currently there are no drugs proven to prevent COVID-19 or to reduce the severity of illness if given as prophylaxis.
- Trial name
- PROTECT-V (NCT04870333)
- Testing
- Niclosamide, Ciclesonide, Sotrovimab
- Where
- 45 sites in United Kingdom
- Volunteers
- 2,240 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Covid19, Kidney Diseases
RECOVAC Repeated Vaccination Study
Rationale: The humoral and cellular immune response after two mRNA vaccinations is severely attenuated in kidney transplant patients compared to controls, especially when their immunosuppressive regimen contains mycophenolate…
- Conditions
- Covid19, Kidney Diseases, Vaccine Response Impaired, SARS-CoV2 Infection
- Trial name
- NCT05030974
- Testing
- mRNA-1273, Ad26.COV2.S vaccine
- Where
- 4 sites in Netherlands
- Volunteers
- 336 people
- Sponsor
- University Medical Center Groningen
Pneumocystis Jirovecii Pneumonia, Kidney Transplantation
Low- vs Standard-Dose TMP-SMX for Prevention of Pneumocystis Pneumonia After Kidney Transplantation
This study is a prospective randomized controlled trial designed to evaluate the efficacy and safety of low-dose versus standard-dose trimethoprim-sulfamethoxazole (TMP-SMX) for the prevention of Pneumocystis jirovecii pneumonia…
- Trial name
- TMP-SMX PJP (NCT07619027)
- Testing
- Trimethoprim-Sulfamethoxazole (TMP-SMX)
- Volunteers
- 1,084 people
- Sponsor
- Anhui Provincial Hospital
Covid19, AKI
Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
The coronavirus (COVID-19) pandemic has created a significant strain on health care resources across the world for managing critically ill patients.
- Conditions
- Covid19, AKI, CKD, ESRD
- Trial name
- NCT04491227
- Where
- 12 sites in United States, Bolivia and 4 more
- Volunteers
- 2,000 people
- Sponsor
- University of California, San Diego
Influenza
Influenza Vaccine in Lung Transplant Patients
This 5-year study was designed to investigate how antibody and T cell responses following influenza vaccine compare among lung transplant patients, patients waiting for lung transplantation, and healthy individuals.
- Trial name
- NCT00205270
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Covid19
Comorbidities and Risk Score in COVID-19 Patients
Retrospective multi-center cohort study. Consecutive patients hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) up to October 2020 will be included.
- Trial name
- Comorbidities (NCT04670094)
- Where
- 5 sites in Italy
- Volunteers
- 4,555 people
- Sponsor
- University of Milano Bicocca
Kidney Transplant, Pancreatic Transplat
SARS-CoV2 (COVID-19) Seroepidemiological Transplanted Subjects (Kidney, Kidney-pancreas, Pancreas, Langerhans Islets)
Evaluate SARS-CoV2 infection and the degree of immunity possibly developed in transplanted population using the Luciferase Immuno Precipitation System (LIPS) test.
- Conditions
- Kidney Transplant, Pancreatic Transplat, Pancreatic Islets Langerhans
- Trial name
- NCT04487197
- Testing
- blood sample for seroepidemiological investigation
- Where
- Italy
- Volunteers
- 282 people
- Sponsor
- Antonio Secchi
Hepatitis B, Chronic (CHB)
Study of AHB-171 in Chronic Hepatitis B Participants
The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative/positive) and nucleos(t)ide analogue (NA)-treated…
- Trial name
- NCT07630727
- Testing
- AHB-171 Injection
- Where
- 10 sites in China
- Volunteers
- 138 people
- Sponsor
- Ausper Biopharma Co., Ltd.